Tenax Therapeutics
Tenax Therapeutics is a clinical-stage biopharmaceutical company developing an oral formulation of levosimendan (TNX-103) to treat pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). The company is running registrational Phase 3 trials, uses a mechanism-focused development strategy targeting splanchnic venodilation via ATP-sensitive potassium channel activation, and is supported by a leadership team with drug development, regulatory and commercial experience and an external scientific advisory board.
Industries
Nr. of Employees
small (1-50)
Tenax Therapeutics
Patents
Pharmaceutical compositions for subcutaneous administration of levosimendan
US-12616694-B2
View DetailsLevosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US-11969424-B2
View DetailsLevosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US-11701355-B2
View DetailsLevosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US-11607412-B2
View DetailsPharmaceutical compositions for subcutaneous administration of levosimendan
US-11213524-B2
View Details
Pharmaceutical compositions for subcutaneous administration of levosimendan
US-12616694-B2
View DetailsLevosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US-11969424-B2
View DetailsLevosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US-11701355-B2
View DetailsLevosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US-11607412-B2
View DetailsPharmaceutical compositions for subcutaneous administration of levosimendan
US-11213524-B2
View DetailsProducts
TNX-103 (oral levosimendan)
An oral formulation of levosimendan being developed to treat pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF); mechanism targets ATP-sensitive potassium channels to cause splanchnic venodilation and reduce pulmonary capillary wedge pressure.
TNX-103
An oral formulation of levosimendan acting as a potassium-ATP channel activator and calcium sensitizer to treat pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
TNX-103 (oral levosimendan)
An oral formulation of levosimendan being developed to treat pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF); mechanism targets ATP-sensitive potassium channels to cause splanchnic venodilation and reduce pulmonary capillary wedge pressure.
TNX-103
An oral formulation of levosimendan acting as a potassium-ATP channel activator and calcium sensitizer to treat pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
Expertise Areas
- Clinical trial management
- Cardiovascular drug development
- Pulmonary hypertension therapeutics (PH-HFpEF)
- Regulatory strategy for late-stage programs
Key Technologies
- Oral drug formulation development
- ATP-sensitive potassium (K-ATP) channel pharmacology
- Calcium-sensitizing pharmacology
- Exercise hemodynamics and invasive PCWP measurement
News & Updates
Presentation/publication of LEVEL trial results at ESC Congress 2026.
Publication reporting hemodynamic and exercise tolerance improvements with levosimendan in PH-HFpEF patients.
Presentation/publication of LEVEL trial results at ESC Congress 2026.
Publication reporting hemodynamic and exercise tolerance improvements with levosimendan in PH-HFpEF patients.